Belief BioMed Reports FDA IND Clearance for Gene Therapy Candidate BBM-D101 for Duchenne Muscular Dystrophy.
The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for Belief BioMed’s (BBM) Duchenne Muscular Dystrophy (DMD) gene therapy candidate, BBM-D101. BBM is a forward-thinking biotechnology company that focuses on creating innovative gene therapies.
The purpose of this open-label, single-dose clinical research was to assess the safety and effectiveness of a single intravenous infusion in DMD patients between the ages of 4 and 9. Because of its modified capsid, BBM-D101 is more effective at transducing muscle tissue. As a result, BBM-D101 is anticipated to have good safety and the suggested clinical dosage is lower than the authorized comparable adeno-associated virus (AAV) gene therapy products.
Learn More: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
